Pamela Weber
Ophthalmology · Shirley, NYNPI 1235111089
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $59,899 of the $89,016 with a category attached, or 67.3%. Novartis accounts for 60.2% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $61,686 and has fallen 98.4% since, to $991 in 2025. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 253 payments — averaging $351.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$54K
- Genentech USA, Inc.$21K
- LKC Technologies, Inc.$6K
- Alimera Sciences, Inc.$3K
- Regeneron Healthcare Solutions, Inc.$2K
- Mallinckrodt Hospital Products Inc.$1K
- plus $2K from 10 others
Across 174 payments — averaging $5274.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$616K
- Regeneron$207K
- GSK$65K
- Ocular Therapeutix, Inc.$15K
- Astellas Pharma Global Development$14K
- AbbVie$787
What the payments were for
- Consulting fees$13,32515%
- Speaking & faculty fees$59,89967%
- Travel & lodging$7,2018%
- Food & beverage$8,59210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 45 | $53,570 |
| Genentech USA, Inc. | 53 | $20,981 |
| LKC Technologies, Inc. | 2 | $6,155 |
| Alimera Sciences, Inc. | 8 | $2,602 |
| Regeneron Healthcare Solutions, Inc. | 55 | $1,862 |
| Mallinckrodt Hospital Products Inc. | 41 | $1,482 |
| Apellis Pharmaceuticals, Inc. | 24 | $1,101 |
| AbbVie(2 entities) | 6 | $212 |
| Ocular Therapeutix, Inc. | 1 | $178 |
| Notal Vision, Inc. | 2 | $171 |
| Carl Zeiss Meditec USA, Inc. | 1 | $169 |
| Bausch & Lomb Americas Inc. | 3 | $167 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $152 |
| Astellas Pharma US Inc | 4 | $88 |
| Biogen | 3 | $69 |
| Genentech, Inc. | 1 | $59 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$89,016 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 12 | $10,574 |
| LumiganBimatoprost | 14 | $6,529 |
| Bromfenac Sodium | 20 | $4,529 |
| Difluprednate | 36 | $3,947 |
| Brimonidine Tartrate | 27 | $2,307 |
| Ketorolac Tromethamine | 33 | $1,212 |
| Dorzolamide Hcl | 58 | $774 |
| Prednisolone Acetate | 14 | $683 |
| Diclofenac Sodium | 50 | $484 |
| Timolol Maleate | 14 | $476 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $322 |
| ErythromycinErythromycin Base | 25 | $233 |
| Latanoprost | 17 | $231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $212 | $17,10326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Shirley
- David RubaltelliBrooklyn$8.9M
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Eric DonnenfeldGarden City$1.4M
- Marguerite McDonaldOceanside$893K
- Joshua YoungNew York$814K
- David KleinmanRochester$730K
- Jonathan JonischGreat Neck$726K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.